PMID: 10607103Mar 1, 1994

Hypnotic drugs, psychomotor performance and ageing

Journal of Sleep Research
K Morgan

Abstract

This review examines studies, reported since 1976, in which the residual effects of hypnotic drugs on psychomotor performance have been evaluated in older people. The 33 studies involved a total of 934 subjects (aged 60-96 y), evaluated 21 different products, utilized 26 test procedures, and reported 169 drug versus placebo (or drug versus drug) comparisons, of which 42 were associated with significant residual impairment. While performance decrements were more associated with longer half-life drugs, repeated dosing, and frailty, these characteristics were often unreliable in predicting outcome. Significant improvements in performance were rare, and usually consistent with practice effects. While this literature provides a useful basis for clinical caution, it is not characterized by experimental rigour, and provides little or no empirical basis for predicting those real-life skills most likely to be affected. Issues of subject selection, experimental design, testing strategies, and data analysis need to be addressed if the risks and benefits of hypnotic drug use in later life are to be more clearly understood.

References

Mar 1, 1977·Clinical Pharmacology and Therapeutics·D J GreenblattR I Shader
Jan 1, 1979·British Journal of Clinical Pharmacology·J R Wittenborn
Jun 26, 1976·British Medical Journal·K AdamW M Hunter
Jan 1, 1977·British Medical Journal·C M CastledenC Hallett
May 1, 1978·British Journal of Clinical Pharmacology·D J Greenblatt, M D Allen
Jun 1, 1976·The British Journal of Psychiatry : the Journal of Mental Science·M Linnoila, M Viukari
Jun 18, 1977·British Medical Journal·D C SkeggJ Perry
May 1, 1976·Social Science & Medicine·I KaracanR L Williams
Dec 1, 1975·The Journal of Nervous and Mental Disease·R A Kleinknecht, D Donaldson
Feb 1, 1992·Journal of the Royal Army Medical Corps·D G Robertson, J D Bennett
Sep 1, 1991·Journal of Clinical Pharmacology·R I ShaderM B Balter
Jan 1, 1991·The American Journal of Psychiatry·H Y McCluskyV Wooten
Feb 17, 1990·BMJ : British Medical Journal·B R Ballinger
Jun 13, 1991·The New England Journal of Medicine·D J GreenblattR I Shader
Dec 15, 1989·JAMA : the Journal of the American Medical Association·W A RayW Downey
Aug 1, 1989·Journal of Clinical Psychopharmacology·M MamelakV Price
Jan 1, 1988·European Journal of Clinical Pharmacology·J C GilbertP Meyer
Aug 1, 1985·British Journal of Clinical Pharmacology·C G SwiftJ Robinson
Jan 1, 1986·Current Medical Research and Opinion·A J Bayer, M S Pathy
Jan 1, 1986·Acta Psychiatrica Scandinavica. Supplementum·M S PathyM J Stoker
Feb 12, 1987·The New England Journal of Medicine·W A RayL J Melton
Jan 1, 1987·Psychopharmacology·J V Hinrichs, M M Ghoneim
Nov 1, 1988·Age and Ageing·A J BlakeE J Bassey
Mar 1, 1988·Journal of Behavior Therapy and Experimental Psychiatry·C A EspieD N Brooks
Jan 1, 1986·Acta Psychiatrica Scandinavica. Supplementum·A J BayerM J Stoker
Jan 1, 1987·Age and Ageing·P W Overstall, P N Oldman
Jun 1, 1987·Journal of the American Geriatrics Society·E GranekL E Klein
Jan 1, 1987·European Journal of Clinical Pharmacology·C M CastledenP St John-Smith
Feb 1, 1986·British Journal of Clinical Pharmacology·A N Nicholson, P A Pascoe
Nov 1, 1973·Archives of General Psychiatry·D M McNair
Jun 1, 1973·Archives of General Psychiatry·H J ParryD I Manheimer
Sep 28, 1973·Psychopharmacologia·A J Bond, M H Lader
Feb 26, 1971·Nature·A J Walters, M H Lader
Jan 1, 1972·Psychopharmacologia·A J Bond, M H Lader
Nov 1, 1971·Archives of General Psychiatry·G D MellingerD I Manheimer
Mar 1, 1980·British Medical Journal·R S BriggsC A Kraft
Jan 1, 1984·Psychopharmacology·K MorganI Oswald
Jan 1, 1984·Neuropsychobiology·M Viukari, P Miettinen
Jan 1, 1983·British Journal of Clinical Pharmacology·R JochemsenD D Breimer
Jan 1, 1982·Psychopharmacology·L C Johnson, D A Chernik
Mar 1, 1983·British Journal of Clinical Pharmacology·R JochemsenD D Breimer
Sep 1, 1980·British Journal of Clinical Pharmacology·I Hindmarch
May 1, 1981·Age and Ageing·J Crooks, I H Stevenson
Sep 1, 1981·International Journal of Dermatology·M S Kramer
Nov 1, 1981·Journal of the American Geriatrics Society·M H Bonnet, M Kramer

Citations

May 23, 1998·Journal of Clinical Pharmacology·G B KaplanR I Shader
Apr 19, 2005·Social Psychiatry and Psychiatric Epidemiology·Matteo BalestrieriFrancesco Donato
Jan 18, 2003·Sleep Medicine Reviews·Daniel F. Kripke
Sep 5, 2002·The Journal of Comparative Neurology·Yaping ChuJeffrey H Kordower
Apr 30, 1999·Journal of Psychopharmacology·G DarcourtJ Lavoisy
Jan 6, 2005·Psychological Bulletin·Dieter VaitlThomas Weiss

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells. It also follows CRISPR-Cas9 approaches to generating genetic mutants as a means of understanding the effect of genetics on phenotype.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Pediculosis pubis

Pediculosis pubis is a disease caused by a parasitic insect known as Pthirus pubis, which infests human pubic hair, as well as other areas with hair including eye lashes. Here is the latest research.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Rh Isoimmunization

Rh isoimmunization is a potentially preventable condition that occasionally is associated with significant perinatal morbidity or mortality. Discover the latest research on Rh Isoimmunization here.

Pharmacology of Proteinopathies

This feed focuses on the pharmacology of proteinopathies - diseases in which proteins abnormally aggregate (i.e. Alzheimer’s, Parkinson’s, etc.). Discover the latest research in this field with this feed.

Enzyme Evolution

This feed focuses on molecular models of enzyme evolution and new approaches (such as adaptive laboratory evolution) to metabolic engineering of microorganisms. Here is the latest research.

Alignment-free Sequence Analysis Tools

Alignment-free sequence analyses have been applied to problems ranging from whole-genome phylogeny to the classification of protein families, identification of horizontally transferred genes, and detection of recombined sequences. Here is the latest research.